Cerevel Therapeutics Holdings, Inc.
NasdaqCM:CERE Stock Report
This company has been acquired The company may no longer be operating, as it has been acquired. Find out why through their latest events.
See Latest Events Cerevel Therapeutics Holdings Future Growth
Future criteria checks 0/6 Cerevel Therapeutics Holdings is forecast to grow earnings and revenue by 17% and 69.6% per annum respectively while EPS is expected to grow by 22.4% per annum.
Key information
17.0%
Earnings growth rate
Biotechs earnings growth 26.7% Revenue growth rate 69.6% Future return on equity n/a Analyst coverage Low
Last updated 02 Aug 2024
Recent future growth updates
Price target increased by 9.7% to US$36.60 Dec 08
Price target decreased by 8.1% to US$34.13 Aug 07
Price target decreased by 7.4% to US$34.38 Aug 03
Price target decreased by 8.8% to US$35.20 May 04
Price target decreased by 9.3% to US$37.09 Mar 16
Price target increased to US$43.29 Sep 20
Show all updates AbbVie Inc. (NYSE:ABBV) completed the acquisition of Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) from FMR LLC and others.
Executive Chairman notifies of intention to sell stock Jul 04
Executive Chairman notifies of intention to sell stock Jun 06
Executive Chairman notifies of intention to sell stock May 13
Cerevel Therapeutics Holdings (NASDAQ:CERE) Has Debt But No Earnings; Should You Worry? Apr 30
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease Apr 19
Executive Chairman notifies of intention to sell stock Apr 03
Executive Chairman notifies of intention to sell stock Mar 03
Executive Chairman notifies of intention to sell stock Jan 11
Price target increased by 9.7% to US$36.60 Dec 08 AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) for $8.2 billion. Dec 07
Independent Director notifies of intention to sell stock Nov 03
Cerevel Therapeutics Holdings, Inc. to Report Q3, 2023 Results on Nov 01, 2023 Oct 14
New minor risk - Shareholder dilution Oct 13 Cerevel Therapeutics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $449.999991 million. Oct 13
Cerevel Therapeutics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $449.999991 million. Oct 12
Executive Chairman notifies of intention to sell stock Sep 10
President recently bought US$2.0m worth of stock Aug 08
Price target decreased by 8.1% to US$34.13 Aug 07
Price target decreased by 7.4% to US$34.38 Aug 03
Executive Chairman notifies of intention to sell stock Jul 14
Cerevel Therapeutics Holdings, Inc. to Report Q2, 2023 Results on Aug 02, 2023 Jul 06
High number of new directors Jul 01
Cerevel Therapeutics Appoints Paul Burgess as Chief Business Development and Strategic Operations Officer, Effective from June 20, 2023 Jun 16
Executive Chairman & CEO notifies of intention to sell stock Jun 05
Cerevel Therapeutics Appoints Susan Altschuller as Chief Financial Officer May 11
Executive Chairman & CEO notifies of intention to sell stock May 08 Cerevel Therapeutics Holdings, Inc. Announces Executive Changes
Price target decreased by 8.8% to US$35.20 May 04
Executive Chairman & CEO notifies of intention to sell stock Apr 14
Price target decreased by 9.3% to US$37.09 Mar 16
Executive Chairman & CEO notifies of intention to sell stock Mar 06
Executive Chairman & CEO exercised options and sold US$1.5m worth of stock Feb 10
Cerevel Therapeutics Holdings, Inc. to Report Q4, 2022 Results on Feb 22, 2023 Feb 02
Executive Chairman & CEO exercised options and sold US$1.3m worth of stock Jan 08
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Could Be 23% Above Their Intrinsic Value Estimate Jan 02
Executive Chairman & CEO exercised options and sold US$1.2m worth of stock Dec 15
Chief Scientific Officer exercised options and sold US$561k worth of stock Nov 04
Cerevel Therapeutics Holdings, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Oct 20
Chief Scientific Officer exercised options and sold US$561k worth of stock Oct 07
Cerevel overweight at Wells Fargo due to candidates with blockbuster potential Sep 26
Price target increased to US$43.29 Sep 20
President exercised options and sold US$371k worth of stock Sep 13
President exercised options and sold US$186k worth of stock Aug 25 Cerevel Therapeutics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $253.75 million. Aug 13
Cerevel Therapeutics prices $300M in notes offering, $254M in stock offering Aug 12
President notifies of intention to sell stock Aug 11
Cerevel Therapeutics GAAP EPS of -$0.61 misses by $0.13 Aug 01
Cerevel Therapeutics Holdings, Inc. to Report Q2, 2022 Results on Aug 01, 2022 Jul 26
Chief Scientific Officer exercised options and sold US$663k worth of stock Jul 23
Chief Scientific Officer notifies of intention to sell stock Jul 09
Cerevel: The Next Big Thing In CNS Disease? Maybe If The Market Wasn't So Crowded Jul 08
Price target decreased to US$39.71 Jul 07
Cerevel Therapeutics Appoints Suneet Varma to Serve as Member of Its Board of Directors Jun 16
Chief Scientific Officer exercised options and sold US$1.4m worth of stock Apr 16
Cerevel Therapeutics Holdings, Inc. to Report Q1, 2022 Results on May 10, 2022 Apr 14
Chief Scientific Officer notifies of intention to sell stock Apr 02
Chief Scientific Officer exercised options and sold US$1.2m worth of stock Mar 19
Chief Scientific Officer exercised options and sold US$895k worth of stock Mar 12
Chief Scientific Officer exercised options and sold US$663k worth of stock Mar 05
Cerevel Therapeutics Holdings, Inc. to Report Q4, 2021 Results on Mar 01, 2022 Feb 17
Cerevel Therapeutics Announces Positive Topline Results for Darigabat in Phase 1 Clinical Trial in Acute Anxiety Feb 16
Chief Scientific Officer exercised options and sold US$663k worth of stock Feb 12
Chief Scientific Officer notifies of intention to sell stock Dec 21
Chief Scientific Officer notifies of intention to sell stock Nov 15
Price target increased to US$46.33 Nov 14
Price target decreased to US$32.67 Nov 12
Price target increased to US$36.33 Oct 29
Cerevel Therapeutics: Pfizer's Neurology Spin-Off Jul 14
Cerevel Therapeutics Holdings, Inc. Announces Positive Topline Results for Cvl-231 in Phase 1B Clinical Trial in Patients with Schizophrenia Jun 30
Cerevel Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to CVL-871 for the Treatment of Dementia-Related Apathy Jun 16
We're Not Very Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn Rate Jun 09
Cerevel Therapeutics Holdings, Inc. to Report Q4, 2020 Results on Mar 24, 2021 Feb 25
Is Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Popular Amongst Institutions? Jan 29
Cerevel Therapeutics Holdings, Inc. Announces Board Appointments Jan 22
Cerevel Therapeutics Announces Appointment of Ruth Mckernan to Board of Directors Dec 10
Cerevel Therapeutics (CERE) Investor Presentation - Slideshow Nov 18
Cerevel Therapeutics reports Q3 results Nov 16
Earnings and Revenue Growth Forecasts NasdaqCM:CERE - Analysts future estimates and past financials data (USD Millions) Date Revenue Earnings Free Cash Flow Cash from Op Avg. No. Analysts 12/31/2026 65 -541 N/A -499 1 12/31/2025 N/A -548 N/A -535 1 12/31/2024 N/A -441 N/A -386 2 3/31/2024 N/A -460 -371 -367 N/A 12/31/2023 N/A -433 -346 -342 N/A 9/30/2023 N/A -393 -336 -332 N/A 6/30/2023 N/A -397 -343 -340 N/A 3/31/2023 N/A -388 -323 -320 N/A 12/31/2022 N/A -352 -297 -293 N/A 9/30/2022 N/A -318 -263 -258 N/A 6/30/2022 N/A -280 -227 -222 N/A 3/31/2022 N/A -243 -218 -210 N/A 12/31/2021 N/A -225 -189 -179 N/A 9/30/2021 N/A -196 -184 -168 N/A 6/30/2021 N/A -173 -167 -144 N/A 3/31/2021 N/A -146 -146 -125 N/A 12/31/2020 N/A -148 -137 -118 N/A 9/30/2020 N/A -175 -124 -112 N/A 6/30/2020 N/A -172 -116 -111 N/A 3/31/2020 N/A -151 -97 -94 N/A 12/31/2019 N/A -128 -72 -71 N/A
Show more
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CERE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CERE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CERE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CERE is forecast to have no revenue next year.
High Growth Revenue: CERE is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CERE's Return on Equity is forecast to be high in 3 years time
Discover growth companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
